Investigators are optimistic about bispecific antibodies (BsAbs) for patients with diffuse large B-cell lymphoma (DLBCL), especially the possibility of combining different BsAbs with distinct targets for stronger treatment outcomes.
The biologics license application for denileukin diftitox has been resubmitted to the FDA for the treatment of cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
Assessing clinical trial effectiveness and real-world effectiveness in the management of multiple myeloma independantexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from independantexpress.com Daily Mail and Mail on Sunday newspapers.